CHARLES TOWN, W.Va., Aug. 28 /PRNewswire-USNewswire/ -- ReBuilder Medical Technologies, Inc. announced today that it has recruited Earl J. Evans Jr., recently retired from AT&T. Mr. Evans has spent his entire career organizing and managing the quality control policies of the electronic assembly of PC boards and other electronic assemblies.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )
The ReBuilder(R) is an electronic device that restores nerve function, increases blood flow, cancels pain, and reduces numbness and tingling that sells for $399-$699 retail and is available on the Internet and through selective physician’s offices.
“We are pleased to add Mr. Evans to our team,” says Adeyemi Bandele, VP ReBuilder Medical, Inc. “We have recently ramped up our production by a factor of three and we have outgrown our manual, paper related based quality control procedures. Although we have classically had more than a 99% pass rate, at the levels of production we now have, and the growth we expect to achieve in the coming months as a result of our expanded marketing efforts, we needed a new, systematic, computerized system to ensure that we maintain our product quality as strong as ever.”
ReBuilder Medical Technologies, Inc. invented, developed, and holds the intellectual property rights to the ReBuilder System(R) for diabetic peripheral neuropathy and the technology to produce micronized amorphous silver ions for diabetic personal hygiene products. According to the American Diabetes Association, there are over 20 million people in the US suffering with diabetes and 30% of these patients will eventually develop the pain, numbness and loss of mobility that accompany diabetic peripheral neuropathy. The overall total economic cost of diabetes is over $132 billion. One of every 10 dollars spent on health costs in America is spent on diabetes. With the graying of the baby boomers, these numbers are expected to climb.
In the coming months ReBuilder Medical will be seeking additional staffing from the pool of retired execs in the community.
According to David Phillips, CEO of ReBuilder Medical Technologies, Inc., the target for the retired executives program is to have the retirees reduce customer queries concerning product quality by 50 percent. This reduction should reduce salaries spent on customer service inquiries as well.
“From a financial point of view,” says Daena Carter, Director of Accounting for ReBuilder Medical Technologies, Inc., “recruiting retired executives from the community makes good sense. They come with an established work ethic, and appreciate the opportunity to still make a contribution. We appreciate them and can accommodate their needs for time off for personal issues relating to health and family.”
Twenty million, eight hundred thousand children and adults, or 7% of the U.S. population suffer from diabetes. Thirty percent of those diagnosed with diabetes will eventually suffer from peripheral neuropathy, pain and numbness in the feet and hands that can lead to complete loss of mobility, gangrene, and eventual amputations. $132 Billion per year is the current cost of treating diabetes, or 1 of every 10 health care dollars spent. Neuropathy sufferers constitute 33% of this market, or 43.56 billion dollars in potential market. ReBuilder Medical Technologies, Inc. is a company in its infancy that has targeted 1% of this market, or, $43.5 million dollars in its next two market years, and is on course to meet this goal. Its primary competition is from drug companies whose drug therapy has proven less successful and prone to negative side-effects and addiction.
About ReBuilder Medical Technologies, Inc.:
ReBuilder Medical Technologies, Inc. is an emerging medical device manufacturer of innovative technologies founded by world renowned medical device inventor David B. Phillips, Ph.D. ReBuilder Medical’s flagship product is its FDA registered ReBuilder System for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) which focus on prescription drugs with powerful side effects, the ReBuilder System is a portable, battery powered medical product that provides a new non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
ReBuilder Medical also manufactures the Phillips Molluscum Treatment system for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses micronized, amorphous silver ions to disable the molluscum virus without side effects. The company is currently performing research and development on a number of other products as well.
Dr. Phillips is CEO of ReBuilder Medical Technologies, Inc. located in Charles Town, WV. He is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System for the early detection of breast cancer and the AcuPen which detects acupuncture points and then treats them.
More information on ReBuilder Medical and its products can be found at: http://www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward- looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words “estimate,” “anticipate,” “expect,” “believe,” and similar expressions are intended to be forward-looking statements.
Photo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comReBuilder Medical Technologies, Inc.
CONTACT: David B. Phillips of ReBuilder Medical Technologies, Inc.,+1-304-725-2202
Web site: http://www.rebuildermedical.com/
